# Astellas and Audax Biosciences Enter Exclusive Option and License Agreement for DAX-044, a Novel Immune-Targeted IL-12 Antibody-Cytokine Fusion for Immuno-Oncology

- Source: PR Newswire
- Published: 2026-10-27T23:30:00+00:00
- Category: Business
- Original: https://www.prnewswire.com/news-releases/astellas-and-audax-biosciences-enter-exclusive-option-and-license-agreement-for-dax-044-a-novel-immune-targeted-il-12-antibody-cytokine-fusion-for-immuno-oncology-302920594.html
- Canonical: https://groundlevelnews.com/story/astellas-and-audax-biosciences-enter-exclusive-option-and-license-agre-fc3994/

- Grants Astellas exclusive option to obtain worldwide license to develop and commercialize DAX-044, with Audax having the option to co-fund and co-promote DAX-044 in Australia and New Zealand - - Audax will fund and continue DAX-044 development into Phase 1 - - Total potential...

_Ground Level News shows a short summary only; the full article and all rights belong to PR Newswire._